During the corresponding time, Urogen Pharma Ltd recorded a revenue increase by 206.17 % year on year, sequentially revenue grew by 42.57 %. While revenue at the Urogen Pharma Ltd 's corporate clients
Urogen Pharma Ltd's Comment on Sales, Marketing and Customers
The company provides treatments for urology and oncology conditions, focusing on the products Jelmyto and Zusduri. Its customer-facing team comprises territory business managers, regional business directors, regional operations managers, clinical nurse educators, field reimbursement managers, key account directors, and medical science liaisons who interact with physicians and C-suite executives. The company targets Medicare patients with supplemental coverage as well as commercial insurance plans that cover Jelmyto. It has agreements with national, regional, and local mixing pharmacies to prepare and dispense Jelmyto. Additionally, the company launched a registry to study real-world outcomes in patients with low-grade upper tract urothelial carcinoma (UTUC) treated with Jelmyto. Zusduri is developed for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC) and is administered locally via catheter into the bladder. The market segments include patients with low-grade UTUC, recurrent low-grade intermediate-risk NMIBC, Medicare patients, and commercial insurance plan holders.
In an era where precision medicine is increasingly at the forefront of cancer treatment, UroGen Pharma Ltd. (Nasdaq: URGN) has unveiled significant findings from the subgroup analyses of its pivotal ENVISION trial. This trial is critical for understanding the effects of UGN-102, an investigational drug aimed at treating patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The recent insights into tumor burden and focality provide new optimism for patients grappling with this challenging condition. Background on UGN-102 and ENVISION TrialUGN-102 represents a novel therapeutic approach for LG-IR-NMIBC, a subtype of bladder cancer characterized by the presence of cancerou...
UGN-102: A Promising New Approach in the Fight Against Bladder Cancer UroGen Pharma Ltd. a pioneering biotech company in the field of urothelial and specialty cancer treatments, has been making significant strides with its investigational therapy UGN-102 (mitomycin), aiming to address a longstanding gap in the treatment landscape. The recent developments concerning UGN-102 have garnered considerable attention as they promise a new hope for patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), a condition currently lacking FDA-approved pharmaceutical interventions. Encouraging Phase 3 ENVISION Trial Results At the Society of Urologic Oncology (SUO) annual meeting in Dalla...
Breaking Boundaries in Urothelial Cancer Treatment: UroGen’s Innovations Show Promising Results By In the relentless quest to redefine cancer treatment, UroGen Pharma Ltd. (Nasdaq: URGN) has been making groundbreaking strides in the field of urothelial and specialty cancers. Recent announcements from this trailblazing biotech company indicate potential shifts in how low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) and upper tract urothelial cancer are treated. With promising results from their ENVISION, ATLAS, and real-world JELMYTO trials, UroGen is poised to bring non-surgical treatment options to the forefront. UGN-102: A Game-Changer for LG-IR-NMIBCOne of the most compelli...
A new analysis of real-world clinical data released by UroGen Pharma Ltd., a leading biotech company focused on developing novel treatment solutions for urothelial and specialty cancers, reveals that JELMYTO (mitomycin for pyelocalyceal solution) has an 86 percent recurrence-free survival rate at 24 months across all studied patient and disease characteristics. These promising results, recently unveiled at the influential American Urological Association Meeting (AUA) 2024 in San Antonio, Texas, are based on the first and largest real-world patient cohort review of JELMYTO s effectiveness. UroGen Pharma is dedicated to the study and fight against urothelial and specialty cancers. In their continuing efforts, ...
In a recent study, UroGen Pharma Ltd. presented the results of their analysis of the ATLAS trial, evaluating the sustained response rates of patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) following treatment with UGN-102. This exciting update provides valuable insights into the long-term efficacy of UGN-102 in both new and recurrent cases of LG-IR-NMIBC.Study Background:NMIBC is a prevalent form of bladder cancer that has a high risk of recurrence and progression. Treating this type of cancer poses several challenges due to its frequently recurring nature and limited therapeutic options. The ATLAS trial was designed to assess the durability of response in LG-IR-NMI...
Urogen Pharma Ltd’s Comment on Sales, Marketing and Customers
The company provides treatments for urology and oncology conditions, focusing on the products Jelmyto and Zusduri. Its customer-facing team comprises territory business managers, regional business directors, regional operations managers, clinical nurse educators, field reimbursement managers, key account directors, and medical science liaisons who interact with physicians and C-suite executives. The company targets Medicare patients with supplemental coverage as well as commercial insurance plans that cover Jelmyto. It has agreements with national, regional, and local mixing pharmacies to prepare and dispense Jelmyto. Additionally, the company launched a registry to study real-world outcomes in patients with low-grade upper tract urothelial carcinoma (UTUC) treated with Jelmyto. Zusduri is developed for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC) and is administered locally via catheter into the bladder. The market segments include patients with low-grade UTUC, recurrent low-grade intermediate-risk NMIBC, Medicare patients, and commercial insurance plan holders.
Sources:
Urogen Pharma Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Urogen Pharma Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Urogen Pharma Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
60.37 %